ストックスクリーナーアプリを入手
4.07
2.16%
-0.09
アフターアワーズ：
4.06
-0.01
-0.25%
Cardiff Oncology Inc (CRDF) 最新ニュース
Cardiff Oncology (NASDAQ:CRDF) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH - Defense World
Brokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Price Target at $11.70 - Defense World
Cardiff Oncology, Inc. (CRDF) Reports 40% Response Rate in mTNBC Trial of Onvansertib + Paclitaxel - MSN
Cardiff Oncology stock initiated with Buy rating at Ladenburg Thalmann By Investing.com - Investing.com Canada
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies - GlobeNewswire
Cardiff Oncology Up 16%, Insider Buyers Are Up 35% - simplywall.st
Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity - Seeking Alpha
Rhumbline Advisers Grows Stock Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Cardiff Oncology stock initiated at Hold by Jefferies on early data concerns - Investing.com
Cardiff Oncology (CRDF) Stock Reacts to Delayed Clinical Data Up - GuruFocus
CRDF Set to Release Key Clinical Data Amid Leadership Changes | CRDF Stock News - GuruFocus
Cardiff Oncology (CRDF) Welcomes New Chief Medical Officer | CRD - GuruFocus
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Offic - GuruFocus
Cardiff Oncology (CRDF) Shares Drop 11% After Leadership Change - GuruFocus
Cardiff Oncology appoints Dr. Roger Sidhu as Chief Medical Officer - MarketScreener
Cardiff Oncology stock falls as new medical chief named (CRDF) - Seeking Alpha
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical - GlobeNewswire
Cardiff Oncology Names New Chief Medical Officer - marketscreener.com
Cardiff Oncology appoints Roger Sidhu as new Chief Medical Officer - Investing.com
Bank of America Corp DE Sells 11,352 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Two Sigma Investments LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Two Sigma Advisers LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
ProShare Advisors LLC Acquires New Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Nuveen Asset Management LLC Acquires 248,850 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Deutsche Bank AG Acquires Shares of 49,566 Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Millennium Management LLC Buys 288,259 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology reports positive trial results for breast cancer treatment - Investing.com India
Cardiff Oncology (CRDF) Reports Promising Phase 1b Trial Results for Breast Cancer Treatment | CRDF Stock News - GuruFocus
Cardiff Oncology Announces Positive Data From Investigator-Initiated Trial Of Onvansertib In Combination With Paclitaxel - marketscreener.com
Cardiff Oncology's Phase 1b Trial for Breast Cancer Treatment Shows 40% Objective Response Rate - marketscreener.com
Cardiff Oncology reports positive trial results for breast cancer treatment By Investing.com - Investing.com Nigeria
Cardiff Oncology Announces Positive Data from Investigator-Initi - GuruFocus
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 - The Manila Times
Cardiff Oncology Reports 40% Objective Response Rate in Phase 1b Trial of Onvansertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer - Nasdaq
Clinical Trial Success: Cardiff Oncology's New Drug Shows 40% Response Rate in Aggressive Breast Cancer - Stock Titan
Cardiff Oncology (CRDF) Emerges as a Prime M&A Target - GuruFocus
SA Asks: Which oncology companies are attractive M&A targets? - Seeking Alpha
Northern Trust Corp Raises Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update - Seeking Alpha
The Manufacturers Life Insurance Company Makes New $67,000 Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Price T Rowe Associates Inc. MD Has $67,000 Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
13,124 Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) Bought by Voya Investment Management LLC - Defense World
Cardiff Oncology Reports Increased Losses Amid Rising R&D Costs - TipRanks
Raymond James Financial Inc. Purchases New Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know - Nasdaq
Cardiff Oncology: Buying The First-Line Onvansertib Strategy (NASDAQ:CRDF) - Seeking Alpha
Barclays PLC Purchases 9,507 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Wells Fargo & Company MN Purchases 8,851 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo
Mariner LLC Makes New $61,000 Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Cardiff Oncology stock target raised to $18 by H.C. Wainwright - Investing.com Canada
Cardiff Oncology (CRDF) Gains Analyst Confidence with Price Target Increase | CRDF Stock News - GuruFocus
2.10%
1.57%
大文字化:
|
ボリューム (24 時間):